Menstrual health innovation shortlist revealed

Femtech World is excited to reveal the shortlist for the inaugural Menstrual Health Innovation award.

The award is one of 11 up for grabs at Femtech World’s second annual awards event, which celebrates the best examples of leadership, innovation and impact in key areas that affect women’s health and wellbeing.

The Menstrual Health Innovation award honours businesses that have made a significant impact by developing products, services or technologies that improve menstrual care, break stigmas, and enhance the lives of women everywhere.

The award is sponsored by Clue  – a period tracking app, a trusted menstrual health resource, and a thought leader in femtech.

By combining science and technology Clue is actively changing the way people learn, access, and talk about menstrual and reproductive health around the world.

A winner from the shortlist will be chosen by the sponsor and announced at a virtual ceremony on May 28.

Congratulations to the shortlisted organisations and thank you to everyone who entered.

Menstrual Health Innovation Shortlist

FlowSense is a revolutionary technology redefining menstrual care for visually impaired women by delivering independence, confidence, and dignity.

Founded by visionary innovator Muna Daud, it introduces the world’s first device designed to detect period blood for visually impaired women, providing real-time feedback through gentle vibrations and audio cues.

This innovation empowers women to independently manage their menstrual cycles without relying on sighted assistance, bridging the accessibility gap in menstrual health solutions.

At OhmBody, we believe women’s wellness deserves more—more innovation, more understanding, and more solutions designed specifically for the unique needs of the female body.

That’s why we’re pioneering a new approach to menstrual health, using advanced wearable neurostimulation to support the body’s natural rhythms.

Our team understands the challenges women face—because a majority of us have lived them.

With a team of women driving exploration and change in clinical research, design, and innovation, we bring both personal insight and deep scientific expertise to our work.

Serac Healthcare is developing a non-invasive diagnostic molecular imaging agent for superficial peritoneal endometriosis (SPE) which has been granted Fast Track Designation by the FDA
Phase III study outline also been agreed.

A non-invasive diagnostic test would lead to earlier more informed treatment decisions, better outcomes, improved quality of life and more efficient use of healthcare resources.

It could also be transformative for the development of desperately needed new therapies for this menstrual health condition.